CLNN insider trading
Consumer DefensiveClene Inc.: insider trade history from SEC Form 4 filings.
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Company website: clene.com
CLNN insider activity at a glance
FilingIQ tracks 152 insider transactions for CLNN in filings since May 24, 2021. The most recent transaction is dated Sep 16, 2026.
Across the full history, 44 open-market purchases
and 83 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CLNN insider trades is 53.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CLNN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Consumer Defensive tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for CLNN?
- FilingIQ tracks 152 Form 4 insider transactions for CLNN (Clene Inc.), covering filings from May 24, 2021 onwards. 3 of those are dated within the last 90 days.
- Are CLNN insiders net buyers or net sellers?
- Across the full Form 4 history for CLNN, 44 transactions (29%) were open-market purchases and 83 (55%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CLNN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is CLNN in?
- Clene Inc. (CLNN) is classified in the Consumer Defensive sector, specifically Packaged Foods, with a current market capitalisation of $47.94M.
Methodology & sources
Every CLNN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.